MACH32 is developing a drug-device combination medical product for early intervention and treatment of severe hemorrhage. This device administers a large-volume dose of the antifibrinolytic drug tranexamic acid (TXA). It simplifies the delivery of TXA, a clinically proven generic drug that reduces the risk of death due to bleeding by ~ 30%. TXA is underused because it is difficult to deliver and requires intravenous access; less than 5% of eligible patients receive TXA in a timely manner. This project focuses on the development of a highly concentrated TXA formulation optimized for simple intramuscular delivery in autoinjector format.
This record is a historical disbursement from Canada's open grants database — it documents a past payment, not an active program accepting applications.
View disbursement record →